Kumar P - Search Results

1

Role of ABC transporters in cancer chemotherapy.

Sun YL, Patel A, Kumar P, Chen ZS. Sun YL, et al. Among authors: kumar p. Chin J Cancer. 2012 Feb;31(2):51-7. doi: 10.5732/cjc.011.10466. Epub 2012 Jan 17. Chin J Cancer. 2012. PMID: 22257384 Free PMC article.

2

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Sun YL, Kumar P, Sodani K, Patel A, Pan Y, Baer MR, Chen ZS, Jiang WQ. Sun YL, et al. Among authors: kumar p. Oncol Rep. 2014 Apr;31(4):1605-12. doi: 10.3892/or.2014.3002. Epub 2014 Jan 28. Oncol Rep. 2014. PMID: 24481648 Free PMC article.

3

Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Sodani K, et al. Among authors: kumar p. Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012. Epub 2014 Feb 22. Biochem Pharmacol. 2014. PMID: 24565910 Free PMC article.

4

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT, Chen ZS. Wang YJ, et al. Among authors: kumar p. Biochem Pharmacol. 2014 Aug 15;90(4):367-78. doi: 10.1016/j.bcp.2014.06.006. Epub 2014 Jun 14. Biochem Pharmacol. 2014. PMID: 24937702 Free PMC article.

5

A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.

Anreddy N, Patel A, Zhang YK, Wang YJ, Shukla S, Kathawala RJ, Kumar P, Gupta P, Ambudkar SV, Wurpel JN, Chen ZS, Guo H. Anreddy N, et al. Among authors: kumar p. Oncotarget. 2015 Nov 17;6(36):39276-91. doi: 10.18632/oncotarget.5747. Oncotarget. 2015. PMID: 26515463 Free PMC article.

6

Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.

Sun YL, Chen JJ, Kumar P, Chen K, Sodani K, Patel A, Chen YL, Chen SD, Jiang WQ, Chen ZS. Sun YL, et al. Among authors: kumar p. PLoS One. 2013;8(2):e55576. doi: 10.1371/journal.pone.0055576. Epub 2013 Feb 5. PLoS One. 2013. PMID: 23393594 Free PMC article.

7

Autophagy and transporter-based multi-drug resistance.

Kumar P, Zhang DM, Degenhardt K, Chen ZS. Kumar P, et al. Cells. 2012 Aug 23;1(3):558-75. doi: 10.3390/cells1030558. Cells. 2012. PMID: 24710490 Free PMC article.

8

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.

Li J, Kumar P, Anreddy N, Zhang YK, Wang YJ, Chen Y, Talele TT, Gupta K, Trombetta LD, Chen ZS. Li J, et al. Among authors: kumar p. Oncotarget. 2017 Sep 16;8(55):93785-93799. doi: 10.18632/oncotarget.21078. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212189 Free PMC article.

9

Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.

Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC. Pawar M, et al. Among authors: kumar p. Eur J Pharmacol. 2007 Jun 1;563(1-3):92-101. doi: 10.1016/j.ejphar.2007.01.059. Epub 2007 Feb 8. Eur J Pharmacol. 2007. PMID: 17349996 Free PMC article.

10

Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.

Sirohi S, Kumar P, Yoburn BC. Sirohi S, et al. Among authors: kumar p. J Pharmacol Exp Ther. 2007 Nov;323(2):701-7. doi: 10.1124/jpet.107.127019. Epub 2007 Aug 14. J Pharmacol Exp Ther. 2007. PMID: 17698975

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13,930 results

Search Page